Transplant is recommended on completion of standard-of-care antibiotics for immunocompetent adults with recurrent infection<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Feb. 26, 2024 (HealthDay News) — Fecal microbiota transplant is recommended on completion of standard-of-care antibiotics to prevent recurrence for adults with recurrent Clostridioides difficile<\/em> (C. difficile<\/em>) infection, according to a clinical practice guideline issued by the American Gastroenterological Association (AGA) and published in the March issue of Gastroenterology<\/em>.<\/p>\n On behalf of the AGA, Anne F. Peery, M.D., from the University of North Carolina at Chapel Hill, and colleagues developed guidelines to provide recommendations on use of fecal microbiota-based therapies in adults with recurrent C. difficile<\/em> infection, severe to fulminant C. difficile<\/em> infection, inflammatory bowel diseases, including pouchitis, and irritable bowel syndrome. The Evidence-to-Decision framework was used to develop recommendations and provide considerations for implementation in clinical practice.<\/p>\n The guideline panel developed seven recommendations. The AGA suggests select use of fecal microbiota-based therapies upon completion of standard-of-care antibiotics to prevent recurrence among immunocompetent adults with recurrent C. difficile<\/em>. Use of conventional fecal microbiota transplant is suggested in mildly or moderately immunocompromised adults with recurrent C. difficile<\/em> infection. The AGA suggests against use of any fecal microbiota-based therapies to prevent recurrent C. difficile<\/em> in severely immunocompromised adults. Select use of conventional fecal microbiota transplant is suggested for adults hospitalized with severe or fulminant C. difficile<\/em> not responding to standard-of-care antibiotics. Except in the context of clinical trials, the AGA suggests against use of conventional microbiota transplant as treatment for inflammatory bowel diseases or irritable bowel syndrome.<\/p>\n “Fecal microbiota transplant is a safe and effective treatment with enough scientific evidence to be offered to most patients with two or more C. diff <\/em>recurrences,” Peery said in a statement.<\/p>\n